331 related articles for article (PubMed ID: 32162707)
1. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
[TBL] [Abstract][Full Text] [Related]
2. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
3. ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling.
Xie B; Zen Q; Wang X; He X; Xie Y; Zhang Z; Li H
Int J Oncol; 2015 May; 46(5):2057-66. PubMed ID: 25738261
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of CLDN6 inhibits cell proliferation, migration, and invasion via regulating EGFR/AKT/mTOR signalling pathway in hepatocellular carcinoma.
Huang L; Zhao C; Sun K; Yang D; Yan L; Luo D; He J; Hu X; Wang R; Shen X; Xiao N; Zhong Z
Cell Biochem Funct; 2020 Jul; 38(5):541-548. PubMed ID: 32056244
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
[TBL] [Abstract][Full Text] [Related]
6. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway.
Tian T; Nan KJ; Guo H; Wang WJ; Ruan ZP; Wang SH; Liang X; Lu CX
Oncol Rep; 2010 Jun; 23(6):1593-600. PubMed ID: 20428814
[TBL] [Abstract][Full Text] [Related]
7. Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway.
Li BH; Wang Y; Wang CY; Zhao MJ; Deng T; Ren XQ
Med Sci Monit; 2018 Nov; 24():8105-8114. PubMed ID: 30418964
[TBL] [Abstract][Full Text] [Related]
8. LncRNA DCST1-AS1 accelerates the proliferation, metastasis and autophagy of hepatocellular carcinoma cell by AKT/mTOR signaling pathways.
Li J; Zhai DS; Huang Q; Chen HL; Zhang Z; Tan QF
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6091-6104. PubMed ID: 31364110
[TBL] [Abstract][Full Text] [Related]
9. TRIM29 modulates proteins involved in PTEN/AKT/mTOR and JAK2/STAT3 signaling pathway and suppresses the progression of hepatocellular carcinoma.
Yin YT; Shi L; Wu C; Zhang MY; Li JX; Zhou YF; Wang SC; Wang HY; Mai SJ
Med Oncol; 2024 Feb; 41(3):79. PubMed ID: 38393440
[TBL] [Abstract][Full Text] [Related]
10. Rap2B knockdown suppresses malignant progression of hepatocellular carcinoma by inactivating the PTEN/PI3K/Akt and ERK1/2 pathways.
Zhu L; Sun Y; Zhang S; Wang L
Mol Cell Biochem; 2020 Mar; 466(1-2):55-63. PubMed ID: 32052247
[TBL] [Abstract][Full Text] [Related]
11. Hsa_circ_0007059 sponges miR-421 to repress cell growth and stemness in hepatocellular carcinoma by the PTEN-AKT/mTOR pathway.
Hui Y; Jin D; Leng J; Liu D; Yuan P; Tang C; Wang Q
Pathol Res Pract; 2022 Jan; 229():153692. PubMed ID: 34847369
[TBL] [Abstract][Full Text] [Related]
12. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug.
Liu C; Zhu X; Jia Y; Chi F; Qin K; Pei J; Zhang C; Mu X; Zhang H; Dong X; Xu J; Yu B
Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(7):823-836. PubMed ID: 33961012
[TBL] [Abstract][Full Text] [Related]
14. Long Non-Coding RNA Linc-USP16 Functions As a Tumour Suppressor in Hepatocellular Carcinoma by Regulating PTEN Expression.
Sui J; Yang X; Qi W; Guo K; Gao Z; Wang L; Sun D
Cell Physiol Biochem; 2017; 44(3):1188-1198. PubMed ID: 29179215
[TBL] [Abstract][Full Text] [Related]
15. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
16. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
Li Y; Ye Y; Feng B; Qi Y
J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of LncRNA NR027113 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma.
Chen Z; Zhou ZY; He CC; Zhang JL; Wang J; Xiao ZY
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7222-7232. PubMed ID: 30468465
[TBL] [Abstract][Full Text] [Related]
18. CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway.
Bi J; Liu Q; Sun Y; Hu X; He X; Xu C
J Recept Signal Transduct Res; 2021 Dec; 41(6):593-603. PubMed ID: 33108937
[TBL] [Abstract][Full Text] [Related]
19. [Inhibitory effect and molecular mechanism of sinomenine on human hepatocellular carcinoma HepG2 and SK-HEP-1 cells].
Tian YY; Ma BB; Zhao XY; Liu C; Li YL; Yu SY; Tian SQ; Pei HL; Lyu YN; Zuo ZP; Wang ZB
Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(17):4702-4710. PubMed ID: 37802809
[TBL] [Abstract][Full Text] [Related]
20. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
